

ABSTRACT

The present invention relates to a novel tricyclic heterocyclic carbaldehyde compound and a pharmaceutical composition, containing same, for IRE1 α inhibition and, more specifically, to a novel tricyclic heterocyclic carbaldehyde compound and a pharmaceutical composition, containing same, for treatment or prevention of IRE1 α -related diseases.